How the TGF-β signal affects cell powerhouses (mitochondria) in blood vessel health
TGF-beta signaling in mitochondrial dynamics
This project looks at how a signaling protein called TGF-β changes mitochondria in blood vessel cells and what that might mean for adults with type 2 (adult-onset) diabetes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11233258 on NIH RePORTER |
What this research studies
Researchers will study two key TGF-β effectors, Smad2 and TAK1, to see how they change mitochondrial shape and function in cells that form blood vessels using lab models of angiogenesis. They will use cell and tissue experiments and molecular tools to watch mitochondrial fusion, fission, and turnover and to map how these processes affect cell metabolism and survival. The team will examine how Smad2 and TAK1 are organized and activated to remodel mitochondria and influence vascular cell behavior. The work is lab-based and focused on molecular mechanisms that relate to vascular health in metabolic disease.
Who could benefit from this research
Good fit: Adults (age 21+) with adult-onset (type 2) diabetes, especially those with vascular complications, would be the most directly relevant group.
Not a fit: Children, people with conditions unrelated to vascular or mitochondrial dysfunction, or anyone seeking an immediate clinical treatment are unlikely to benefit directly from this basic laboratory research.
Why it matters
Potential benefit: If successful, this work could reveal new targets to protect blood vessels and metabolic health in people with type 2 diabetes.
How similar studies have performed: Previous research has linked TGF-β to cell metabolism and mitochondrial changes, but the direct roles of Smad2 and TAK1 in mitochondrial remodeling are largely novel and not yet well tested.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Lee, Nam Y — University of Arizona
- Study coordinator: Lee, Nam Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.